|

Platelet Rich Plasma for Musculoskeletal Conditions

RECRUITINGN/ASponsored by University of Utah
Actively Recruiting
PhaseN/A
SponsorUniversity of Utah
Started2025-12-29
Est. completion2035-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* 18+ years old
* Musculoskeletal pathology that may benefit from a PRP injection
* Failed other conservative treatments

Exclusion Criteria:

* No active malignancy
* No active infection in the area of injection
* No platelet disorder
* No active systemic infections
* No patients currently undergoing dialysis

Conditions10

ArthritisElbow OsteoarthritisEpicondylitis of the ElbowOsteoarthritis (OA)Osteoarthritis (OA) of the HipOsteoarthritis (OA) of the KneeOsteoarthritis (OA) of the ShoulderOsteoarthritis AnklePlantar Fasciitis of Both FeetTendinopathy

Interventions1

Locations1 site

University of Utah Orthoaedic Center
Salt Lake City, Utah, 84111-1334
Luke Johnson, BS8012133379luke.a.johnson@hsc.utah.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.